GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » ROE %

Coherus BioSciences (Coherus BioSciences) ROE %

: 0.00% (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Coherus BioSciences's annualized net income for the quarter that ended in Dec. 2023 was $-318.6 Mil. Coherus BioSciences's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-163.5 Mil. Therefore, Coherus BioSciences's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Coherus BioSciences's ROE % or its related term are showing as below:

During the past 12 years, Coherus BioSciences's highest ROE % was 269.68%. The lowest was -1,778.45%. And the median was -713.65%.

CHRS's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.11
* Ranked among companies with meaningful ROE % only.

Coherus BioSciences ROE % Historical Data

The historical data trend for Coherus BioSciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 269.68 68.49 -151.62 - -

Coherus BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Coherus BioSciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences ROE % Distribution

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's ROE % distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's ROE % falls into.



Coherus BioSciences ROE % Calculation

Coherus BioSciences's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-237.892/( (-137.418+-193.425)/ 2 )
=-237.892/-165.4215
=N/A %

Coherus BioSciences's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-318.612/( (-133.599+-193.425)/ 2 )
=-318.612/-163.512
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Coherus BioSciences  (NAS:CHRS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-318.612/-163.512
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-318.612 / 366.096)*(366.096 / 606.6935)*(606.6935 / -163.512)
=Net Margin %*Asset Turnover*Equity Multiplier
=-87.03 %*0.6034*N/A
=ROA %*Equity Multiplier
=-52.51 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-318.612/-163.512
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-318.612 / -318.612) * (-318.612 / -275.62) * (-275.62 / 366.096) * (366.096 / 606.6935) * (606.6935 / -163.512)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.156 * -75.29 % * 0.6034 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Coherus BioSciences ROE % Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (Coherus BioSciences) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009